CEO Executive AssistantResearch and development is the engine of pharmaceutical value creation, but it is also the greatest source of capital destruction in the industry. The majority of drug candidates that enter clinical development fail to reach approval, and as McKinsey research on pharmaceutical R&D productivity documents, the average cost of bringing a single drug to market exceeds two billion dollars when accounting for the full portfolio of failures. Against this backdrop, the pharmaceutical CEO’s most consequential operational role may be governing the R&D portfolio: deciding which programs to advance, which to terminate, how to allocate finite capital and talent across competing opportunities, and how to structure the decision-making processes that make these choices with rigor and speed.
This article examines the operational frameworks that pharma CEOs use to manage R&D portfolio governance, pipeline prioritization, stage-gate processes, and the cross-functional coordination that determines whether a pharmaceutical R&D organization makes good decisions at scale.
The CEO’s Role in R&D Portfolio Governance
The pharmaceutical CEO is not the head of research. They do not typically manage individual scientific programs, review preclinical data packages, or direct the work of discovery teams. But they are responsible for the operational system through which portfolio decisions are made: the governance structures, decision frameworks, resource allocation processes, and performance management systems that shape what gets funded, what gets stopped, and what gets advanced.
Portfolio governance failure in pharma takes several recurring forms. One is the failure to kill underperforming programs early enough, driven by sunk cost bias, scientific attachment, or the career risk aversion of leaders who champion specific programs. Another is the failure to reallocate capital from declining legacy programs to high-potential emerging assets. A third is governance by consensus that slows critical decisions and allows programs with marginal probability of success to persist through attrition rather than decisive action.
The CEO must build governance systems that counteract these failure modes: systems with clear decision rights, explicit risk criteria, independent scientific review, and cultural norms that reward honest assessment over advocacy.
Portfolio Strategy: Setting the Investment Framework
Before individual program decisions can be made well, the CEO needs a portfolio strategy that defines the organization’s investment thesis. This is a set of explicit choices about where the company will and will not play.
Therapeutic area focus is typically the primary dimension. Most mid-size pharma companies cannot sustain competitive R&D capabilities across more than two or three therapeutic areas. The CEO must define where the organization has genuine scientific differentiation and where it is competing on the same evidence base as larger, better-resourced rivals. Programs outside the focus areas consume capital and talent disproportionate to their strategic value.
Modality strategy is the second dimension: will the organization develop small molecules, biologics, cell and gene therapies, RNA-based medicines, or some combination? Each modality requires distinct manufacturing capabilities, clinical expertise, and regulatory infrastructure. The CEO must ensure the portfolio strategy aligns with the organization’s manufacturing and development capabilities, or explicitly plan to acquire capabilities needed for emerging modalities.
Risk-return balance across the portfolio should be managed at the CEO level. A portfolio composed entirely of high-risk, first-in-class programs produces either large wins or extended droughts. A portfolio weighted toward low-risk, follow-on programs generates more predictable near-term revenues but limited premium commercial opportunities. Most pharmaceutical companies aim for a balance, and the CEO should be able to articulate the intended balance and defend it to the board.
Stage-Gate Operations: Translating Strategy into Decisions
Stage-gate processes are the operational mechanism through which portfolio strategy is translated into individual program decisions. A stage-gate system defines the criteria that must be met to advance a program from one development phase to the next, the evidence that must be generated to evaluate against those criteria, the governance body that makes advancement decisions, and the decision options available (advance, pause, pivot, terminate).
The CEO should ensure the stage-gate system has several operational properties. First, it must have explicit, pre-agreed advancement criteria for each gate. Criteria that are defined retrospectively, after the data is known, invite motivated reasoning. Stage-gate criteria should be set when the program advances into the prior stage, based on the scientific and commercial thresholds that must be demonstrated for the investment to be justified at the next level of commitment.
Second, the system must have meaningful termination authority at every gate. Gates that never terminate programs are not governance mechanisms; they are scheduling systems. The CEO should track termination rates at each gate and investigate governance bodies that consistently advance programs with weak data.
Third, stage-gate reviews should be conducted by people who are independent of the program team. Scientific advisory boards, external clinical experts, and cross-functional review committees that include finance, market access, and commercial perspectives alongside scientific and clinical expertise produce better decisions than reviews dominated by program champions.
Fourth, the stage-gate calendar should be protected from commercial pressure. In companies where late-stage programs have large projected revenues, there is persistent pressure to advance programs with insufficient evidence to protect revenue forecasts. The CEO must establish and enforce norms that separate commercial projections from advancement decisions, while ensuring commercial viability is assessed as part of each gate.
Resource Allocation Operations
Pipeline prioritization is meaningless without the resource allocation system to execute it. The CEO must build operational processes that ensure capital, clinical capacity, manufacturing slots, and talent flow toward the portfolio’s highest-priority programs.
Annual portfolio resource allocation should be a formal process, not an incremental adjustment to the prior year’s budget. The process should begin with an updated portfolio valuation, modeling the probability-adjusted net present value of each program given current evidence and market assumptions. Programs should be ranked by both value potential and strategic fit, and resources should be allocated accordingly, with explicit reductions for lower-priority programs rather than across-the-board cuts.
Clinical capacity is often the binding constraint in pharmaceutical R&D. The number of patients that can be enrolled in clinical trials, the capacity of clinical operations teams to manage studies, and the availability of manufacturing material to supply trials all limit how many programs can be advanced simultaneously. The CEO should establish a clinical capacity planning process that makes these constraints visible to the portfolio governance body and forces explicit prioritization decisions rather than allowing all programs to compete for shared resources.
Talent is another critical constrained resource. Key scientific and clinical leaders can typically provide meaningful input to a limited number of programs simultaneously. The portfolio should be sized to the organization’s talent base, with explicit decisions about which programs get access to the most experienced leaders and which proceed with more junior teams.
External Innovation and Business Development Integration
No pharmaceutical company can generate enough internal innovation to maintain a competitive pipeline through organic R&D alone. Licensing, co-development partnerships, acquisitions, and equity investments in early-stage biotechs are all components of the external innovation strategy that the CEO must integrate with internal portfolio management.
The CEO should establish an external innovation governance process that aligns business development activity with the portfolio strategy. Opportunities in therapeutic areas or modalities outside the focus areas should require a higher bar for investment, and the governance process should prevent business development from pursuing attractive assets that fragment the portfolio.
Integration planning for acquired or in-licensed programs should be a governance requirement, not an afterthought. Many pharmaceutical acquisitions fail to realize their value because the acquired program is poorly integrated into the acquiring company’s development infrastructure. The CEO should require integration plans as part of the deal approval process, covering scientific governance, clinical operations handoff, manufacturing scale-up, and the retention of key talent from the acquired organization.
For a structured framework covering the full range of pharmaceutical operational priorities, our pharma operations resource provides a CEO-level checklist organized by organizational stage.
Portfolio Performance Measurement
Portfolio governance requires a performance measurement system that tracks both the health of the pipeline and the quality of portfolio decision-making. These are distinct: a pipeline can appear healthy in the short term while the underlying decision quality is poor, with consequences that manifest only years later.
Pipeline health metrics include: the number of programs at each development stage, the projected value of the pipeline at each stage weighted by probability of success, the diversity of the pipeline across therapeutic areas and modalities, and the time-to-market for programs relative to competitive programs targeting the same indication.
Decision quality metrics are harder to construct but more revealing. Retrospective analysis of stage-gate decisions, comparing advancement decisions with ultimate program outcomes, reveals whether the governance system is accurately assessing program potential. A governance system that consistently advances programs that ultimately fail, and consistently terminates programs that would have succeeded if pursued by others, is a broken system regardless of how many programs it contains.
The CEO should conduct annual retrospective reviews of portfolio decision quality, examining programs that were terminated and later vindicated, programs that advanced and subsequently failed, and programs where critical pivots were made too slowly. These reviews should inform governance process improvements, not individual accountability.
Organizational Design for R&D Operations
The organizational structure supporting R&D portfolio management significantly influences both decision quality and execution speed. The CEO must balance several structural tensions: centralization versus decentralization of scientific expertise, therapeutic area focus versus functional efficiency, and internal capability versus external partnerships.
Matrix organizations, which are common in large pharmaceutical companies, create coordination complexity that slows decisions and diffuses accountability. The CEO should periodically examine whether the organizational structure is serving the portfolio strategy or constraining it. Reorganizations should be driven by strategic needs, not by the preferences of individual leaders.
The relationship between the Chief Scientific Officer (CSO) and the Chief Medical Officer (CMO) is a critical structural interface. In some organizations, these roles are combined; in others, they are separate with clear demarcation between preclinical and clinical governance. The CEO should ensure the governance structure reflects the organization’s actual development model and that the interface between preclinical and clinical decision-making is explicit.
Crisis Decision-Making in the R&D Portfolio
R&D portfolios inevitably face crises: unexpected clinical failures, safety signals that require trial holds, competitive breakthroughs that undermine program rationale, and regulatory decisions that require rapid program pivots. The CEO needs protocols for making high-stakes portfolio decisions under time pressure and uncertainty.
Crisis portfolio decisions are most likely to go wrong when they are made by too small a group (CEO and CSO alone, without commercial or regulatory input), when they are made too slowly (allowing uncertainty to paralyze the organization), or when they are made under unrealistic commercial pressure (to preserve revenue forecasts rather than to optimize scientific and patient outcomes).
Pre-established crisis decision protocols, defining who must be involved in different types of decisions and what information is required before a decision can be made, significantly improve decision quality under pressure. The CEO should develop these protocols in advance and review them with the governance team periodically so they are available when needed.
Our pharma ops guide provides additional context on how R&D portfolio governance connects to the broader operational management system for pharmaceutical companies.
Conclusion
R&D portfolio governance is the operational discipline through which pharmaceutical companies translate scientific capability into commercial value. CEOs who build rigorous stage-gate systems, maintain disciplined investment frameworks, integrate external innovation effectively, and measure decision quality rather than just pipeline size consistently outperform those who allow portfolio decisions to be driven by advocacy, inertia, or commercial pressure. In an industry where the stakes of portfolio decisions are measured in billions of dollars and years of patient waiting, operational excellence in R&D governance is among the most valuable capabilities a pharmaceutical CEO can build.
Related Reading
For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.